According to our results, a combination therapy of anti‐PD‐1 or anti‐CTLA4 ICIs and EBV‐CTLs may yield favourable clinical outcomes for patients with NPC. This evidence concerns the gene CTLA4 and nasopharyngeal carcinoma.